|Bid||30.75 x 0|
|Ask||30.89 x 0|
|Day's Range||30.75 - 32.19|
|52 Week Range||14.01 - 36.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.40|
NEW YORK, NY / ACCESSWIRE / July 9, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with ...
PDUFA Date Set for February 25, 2019 LAVAL, Quebec , July 9, 2018 /PRNewswire/ -- – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International, ...
A controversy over massive price increases, along with other scandals, wrecked Valeant Pharmaceutical International Inc.’s reputation as well as its stock price in recent years. Valeant (VRX) is using two techniques to raise prices on one of its best-selling drugs: it has increased the size of the package of its diarrhea medication, called Xifaxan, by 43%, from 42 pills to 60, and it is charging about 6% more per milligram, according to an analyst note by Mizuho’s Irina Koffler. The larger packaging has helped boost sales volumes, Koffler said.
Shares of Valeant Pharmaceuticals International (VRX) sold off earlier this month after the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis Duobrii. However, Mizuho's Irina Koffler argues that the selloff is overdone, as she believes that Xifaxan, the traveler's diarrhea and irritable-bowel-syndrome treatment, is Valeant's key growth driver, rather than its dermatology portfolio. She reiterated a Buy rating on Valeant Friday and raised her price target by $4 to $31. The SPDR S&P Pharmaceuticals ETF (XPH) is up 0.5% to $43.18 and the Health Care Select Sector SPDR ETF (XLV) is up 0.8% to $83.92.
Valeant Pharmaceuticals (VRX) stock has been falling in June. Valeant’s division Ortho Dermatologics received a CRL (complete response letter) from the FDA on June 18 for its new drug application for Duobril, which treats plaque psoriasis. Valeant’s Siliq, which treats moderate to severe psoriasis, received FDA approval earlier.
By now, we've all heard of the horrors of the U.S. opioid crisis: Well over 100 people a day die by opioid overdose, and a quarter of all patients who are prescribed opioids for chronic pain–11.5 million people–end up misusing the medications. Valeant is off 0.5% to $23.19 this morning.
Salix Sales Force to Begin Promoting LUCEMYRA to Primary Care and Pain Management Physicians LUCEMYRA is the First and Only Non-Opioid Medication Approved for Mitigation of Opioid Withdrawal Symptoms LOUISVILLE, ...
Cindy Eckert is the anti-Martin Shkreli — after the billion-dollar Valeant debacle, the founder of Sprout Pharmaceuticals is back as CEO and she's slashed the price of the little pink libido pill for women. Here's what she learned from the experience and where she goes from here.
Shares of Valeant Pharmaceuticals International (VRX) started the week off on a down note, on news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment Monday, and the shares are falling again today. Cantor Fitzgerald argued that the letter wasn't anything for investors to worry about, and today H.C. Wainwright analyst Raghuram Selvaraju argues much the same thing, even if he has a Neutral rating on the stock. Selvaraju writes that although the psoriasis drug, Duobrii, was one of the "Significant Seven" products around which he saw the "new" Valeant would be built, he--much like Cantor--hasn't included sales from the treatment in his model for 2018.
Valeant Pharmaceuticals International Inc.’s rebound from this year’s low in March was stopped in its tracks after U.S. regulators rejected its application for a plaque psoriasis lotion, Duobrii, that management saw as the first of many new drugs to hit the market in the next few years. Trading volume was more than 1.5 times the full-day average of the past three months as investors retreated even after the company pointed out that the Food and Drug Administration’s ruling was related to its pharmacokinetic data and said management is working to “resolve this matter expeditiously” and has already requested a meeting with regulators. Wells Fargo analyst David Maris warned that an approval may be delayed by six to nine months depending on Valeant’s need to generate additional data.
Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion. A possible delay in approval of the treatment could be a blow to the company, as the treatment is one of the seven products, dubbed as the "Significant Seven", highlighted in Valeant's pipeline projected to raise over $1 billion over the next five years. "We wonder if Valeant will need to update this expectation for the 'Significant Seven' peak sales following the setback to Duobrii," Wells Fargo analyst David Maris said in a note.
Shares of Valeant Pharmaceuticals International (VRX) are lower on Monday, following news that the company received a Complete Response Letter from the Food and Drug Administration concerning its plaque psoriasis treatment. Chen writes that there are three reasons why she still has confidence in Valeant: The fact that the pharmacokinetic (PK) data has been available for "years," that in April, the Journal of American Academy of Dermatology published positive results from two Phase 3 randomized double-blind clinical trials for the first time, and sales of Duobrii wouldn't have been critical to Valeant's 2018 sales, given that it would have launched late in the year. Chen notes that the FDA's letter related to Duobrii's PK data, and Valeant is working with the agency.
Among the companies with shares expected to trade actively in Monday's session are Apple, Facebook, Alphabet, Comcast, General Electric and General Motors.
Valeant Pharmaceuticals International Inc. shares dropped 5.4% in premarket trade on Monday on news that the Food and Drug Administration failed to approve the company's lotion intended to treat plaque psoriasis. In a "complete response letter" notifying the company of the decision, the regulator noted questions about pharmacokinetic data, but did not specify problems with how well the product, Duobrii, works, nor with chemistry, manufacturing and controls processes, the company said. Valeant says it plans to work with the FDA to resolve the matter.
LAVAL, Quebec, June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis. The CRL only noted questions regarding pharmacokinetic data," said Joseph C. Papa, chairman and CEO, Valeant. "We are working to resolve this matter expeditiously and have already requested a meeting with the FDA.
Now Available at Major U.S. Retailers LAVAL, Quebec , June 14, 2018 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Valeant Pharmaceuticals International ...
Eckert stopped by Fortune to talk about her "real launch" of Sprout's Addyi after getting it back from Valeant Pharmaceuticals.
Yahoo Finance's Alexis Christoforous and Jared Blikre break down the latest market action after the Trump administration released details on the latest round of China tariffs, to which China has responded in kind. In other news, the June Empire State Manufacturing Survey beat Wall Street expectations on nearly every front.